Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Harmaline is a naturally occurring beta-carboline alkaloid found primarily in the plant *Peganum harmala* and other sources. It is a reversible inhibitor of monoamine oxidase A (MAO-A), classifying it as a RIMA (reversible inhibitor of MAO-A). Harmaline exhibits central nervous system stimulant properties and mild psychedelic effects with pronounced physical side effects. Its mechanism of action includes inhibition of MAO-A, leading to increased levels of neurotransmitters such as serotonin and dopamine in the brain. Harmaline also acts as an acetylcholinesterase inhibitor, histamine N-methyltransferase inhibitor, and has weak affinity for serotonin 5-HT2A and 5-HT2C receptors. At high doses in animal models, it stimulates striatal dopamine release and can induce tremor by modulating T-type calcium channels within the inferior olive-cerebellar circuitry. Harmaline has been studied for its antiviral activity against herpes simplex virus types 1 and 2 by inhibiting viral transcription at noncytotoxic concentrations[1][2][3][5][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on harmaline.